Loading…
Japanese maker of OTC eye drops, pharmaceuticals and skincare, known for the Hada Labo skincare brand.
Japanese maker of OTC eye drops, pharmaceuticals and skincare, known for the Hada Labo skincare brand.
Sells over-the-counter eye drops and skincare through drugstores and retailers, with brands advertised heavily to keep shelf space. Its portfolio also includes the Mentholatum and Obagi brands, which give it a sizeable business outside Japan, and Hada Labo is sold widely across Asia.
In one line: Japan's Bausch + Lomb, plus a skincare business like a smaller L'Oreal.
Moat: narrow (brand, IP / patents). Leading eye-drop brand recognition and Hada Labo skincare formulation IP with global reach.
Headquarters: Osaka, Japan · Founded: 1899 · Employees: 9,292
Size Rohto Pharmaceutical (4527.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $3.97B, the 288th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,696 on 6 Nov 2026.
Performance Over six months the shares gained 17.2%, against -5.7% for the median peer and +1.8% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 9.7% over the last twelve months (peer median +5.2%); the operating margin is 12.1% (peer median 14.3%).
Valuation It trades at 16.7× forward earnings against a peer median of 19.9× (8th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥353B | ¥344B | ¥309B | ¥271B | ¥239B |
| Revenue growth | — | +11% | +14% | +13% | — |
| Gross profit | ¥196B | ¥183B | ¥169B | ¥155B | ¥135B |
| EBITDA | ¥60.5B | ¥58.1B | ¥51.1B | ¥48.9B | ¥41.3B |
| Net income | ¥33.1B | ¥34.2B | ¥30.8B | ¥30.9B | ¥26.4B |
| Free cash flow | n/a | ¥36.3B | ¥27.8B | ¥26.3B | ¥22.5B |
| Capital expenditure | n/a | ¥26.3B | ¥10.6B | ¥8.91B | ¥9.91B |
| Total debt | ¥58.1B | ¥64.2B | ¥61.2B | ¥12.8B | ¥13.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Rohto Pharmaceutical 4527.T | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% |
| Kobayashi Pharmaceutical 4967.T | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% |
| L'Oreal OR.PA | $268B | +25% | +3% | 21% | 32.8× | 18.1% |
| Santen Pharmaceutical 4536.T | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% |
| Lion 4912.T | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% |
| Shiseido 4911.T | $9.52B | +20% | +5% | 4% | 32.8× | 17.5% |
| KOSE 4922.T | $2.16B | +7% | +3% | 4% | 27.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4527.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | +1.7% | 9th lowest of 21 |
| 6-month return | +17.2% | -5.7% | 7th highest of 21 |
| Distance from 52-week high | -13.7% | -24.1% | 8th highest of 21 |
| Revenue growth (TTM) | +9.7% | +5.2% | 7th highest of 21 |
| Operating margin | 12.1% | 14.3% | 9th lowest of 21 |
| Forward P/E | 16.7× | 19.9× | 8th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -2.1% | 4.7% | 6th least demanding of 20 |
| Growth delivered (Del g) | +13.7% | +6.6% | 8th highest of 20 |
| Hurdle (Req g minus delivered) | -15.8 pp | -2.8 pp | 5th least demanding of 20 |
| ROIC minus cost of capital | +4.2 pp | +5.5 pp | 9th lowest of 20 |
| EV / EBITDA | 10.2× | 17.4× | 5th cheapest of 15 |
| Net debt / EBITDA | -0.4× | -0.8× | 7th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rohto Pharmaceutical 4527.T | Japan | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% | +13.7% |
| Interparfums ITP.PA | France | $3.65B | +72% | -4% | 18% | 27.5× | 15.9% | +19.6% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.83B | -23% | +9% | 28% | 32.2× | 30.8% | +4.5% |
| Cupid CUPID.NS | India | $4.83B | +158% | +122% | 34% | n/a | n/a | n/a |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.92B | -28% | +32% | 31% | 15.0× | 4.7% | +41.1% |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Reynolds Consumer Products REYN | United States | $5.08B | +10% | +2% | 14% | 14.6× | -0.2% | +2.7% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Amorepacific 090430.KS | South Korea | $6.03B | -1% | +10% | 9% | 23.8× | 4.0% | -0.8% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| e.l.f. Beauty ELF | United States | $6.85B | +91% | +31% | 12% | 35.4× | 27.9% | +38.8% |
| APR 278470.KS | South Korea | $7.04B | -40% | +119% | 23% | 17.4× | -1.4% | +47.3% |
| Dabur India DABUR.NS | India | $7.13B | -19% | +9% | 15% | 32.1× | 27.3% | +6.6% |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |